The Pharmacology of T Cell Therapies

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Adoptive cellular therapy, utilizing T cells with tumor specificity via T cell receptors (TCRs) or chimeric antigen receptors (CARs), is advancing in clinical trials.
• Two CAR T-cell therapies received US regulatory approval in 2017, highlighting the clinical significance of this approach.

Purpose of the Study:

• To review T-cell therapies in clinical development.
• To examine factors influencing cellular kinetics post-infusion and their link to anti-cancer activity.
• To discuss the unique toxicities of T-cell therapies, focusing on cytokine release syndrome and neurotoxicity.

Main Methods:

• Literature review of adoptive T-cell therapies.
• Analysis of factors affecting T-cell kinetics and efficacy.
• Discussion of adverse events, including cytokine release syndrome and neurotoxicity.

Main Results:

• T-cell therapies have distinct pharmacology compared to traditional drugs.
• Cellular kinetics significantly impact anti-cancer activity.
• Cytokine release syndrome and neurotoxicity are key toxicities with knowledge gaps.

Conclusions:

• Effective clinical use of T-cell therapies requires understanding their unique pharmacology and kinetics.
• Further research is needed to address knowledge gaps in managing T-cell therapy-related toxicities.